Risk of Osteonecrosis of the Jaw in Cancer Patients Receiving Denosumab: a Meta-analysis of Seven Randomized Controlled Trials

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2013 Apr 23

PMID 23605142

Citations 69

Authors

Wei-Xiang Qi

Li-Na Tang

Ai-Na He

Yang Yao

Zan Shen

Affiliations

Soon will be listed here.

Abstract

Aims: The aim of this study is to gain a better understanding of the overall incidence and risk of osteonecrosis of the jaw (ONJ) in cancer patients receiving denosumab.

Methods: We performed a meta-analysis of relevant randomized controlled trials identified in Pubmed, Embase, and Cochrane databases. Abstracts presented at the conferences were also searched. Overall incidence rates, relative risk (RR), and 95 % confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: A total of 8963 patients with a variety of solid tumors from 7 randomized controlled trials (RCTs) were included for the meta-analysis. The overall incidence of ONJ in cancer patients receiving denosumab was 1.7 % [95 % CI: 0.9-3.1 %]. Also, the use of denosumab was associated with significantly increased risk of ONJ in comparison with bisphosphonates (BPs)/placebo treatment (RR 1.61, 95 % CI: 1.05-2.48, P = 0.029). Subgroup analysis based on controlled therapies demonstrated an increased risk of ONJ in denosumab therapy, when compared with BPs (RR 1.48, 95 % CI: 0.96-2.29, P = 0.078) or placebo (RR 16.28, 95 % CI: 1.68-158.05, P = 0.017). Similar results were observed in prostate cancer (RR 3.358, 95 % CI: 1.573-7.166, P = 0.002) while there was a non-significantly increased risk of denosumab-related osteonecrosis of the jaw (DONJ) in non-prostate cancers (RR 1.142, 95 % CI: 0.678-1.921, P = 0.618).

Conclusions: The use of denosumab is associated with an increased risk of developing ONJ when compared with BP treatment or placebo, although the increased risk was not statistically significant between denosumab and BP treatment. Further studies are still needed to establish guidelines for the prevention and effective treatment of ONJ.

Citing Articles

Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw.

Ruan H, Chen H, Hou J, An J, Guo Y, Liu B J Bone Oncol. 2024; 49:100650.

PMID: 39651419 PMC: 11621599. DOI: 10.1016/j.jbo.2024.100650.

A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.

Hanna R, Miron I, Dalvi S, Arany P, Bensadoun R, Benedicenti S Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204116 PMC: 11357434. DOI: 10.3390/ph17081011.

The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.

Lim A, Park W, Moon S, Kim M, Lee S BMC Health Serv Res. 2024; 24(1):412.

PMID: 38566103 PMC: 10988945. DOI: 10.1186/s12913-024-10859-7.

A Narrative Review of Osteonecrosis of the Jaw: What a Clinician Should Know.

Sharma S, Shankar R, Ravi Kiran B, Breh R, Sarangi S, Upadhyay A Cureus. 2024; 15(12):e51183.

PMID: 38283469 PMC: 10817767. DOI: 10.7759/cureus.51183.

Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer.

Dominguez Senin L, Morales Pancorbo D, Garces M, Santos-Rubio M, Bayo Calero J Curr Oncol. 2024; 31(1):250-259.

PMID: 38248101 PMC: 10814865. DOI: 10.3390/curroncol31010016.

References

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Langer C, Hirsh V . Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2009; 67(1):4-11. DOI: 10.1016/j.lungcan.2009.08.020. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Rastogi A, Rattan V, Bhadada S . Osteonecrosis of jaw associated with bisphosphonate use. Indian J Endocrinol Metab. 2012; 16(3):450-2. PMC: 3354860. DOI: 10.4103/2230-8210.95711. View

Qi W, Wang Q, Jiang Y, Sun Y, Tang L, He A . Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PLoS One. 2013; 8(2):e55637. PMC: 3568141. DOI: 10.1371/journal.pone.0055637. View

Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P . Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2010; 40(3):277-84. DOI: 10.1016/j.ijom.2010.11.002. View

Coleman R . Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-94. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z. View

Peddi P, Lopez-Olivo M, Pratt G, Suarez-Almazor M . Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2012; 39(1):97-104. PMC: 3691016. DOI: 10.1016/j.ctrv.2012.07.002. View

Van Poznak C, Temin S, Yee G, Janjan N, Barlow W, Biermann J . American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011; 29(9):1221-7. DOI: 10.1200/JCO.2010.32.5209. View

10.

Voss P, Joshi Oshero J, Kovalova-Muller A, Veigel Merino E, Sauerbier S, Al-Jamali J . Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg. 2012; 40(8):719-25. DOI: 10.1016/j.jcms.2012.01.005. View

11.

Choueiri T, Schutz F, Je Y, Rosenberg J, Bellmunt J . Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28(13):2280-5. DOI: 10.1200/JCO.2009.27.2757. View

12.

Paller C, Carducci M, Philips G . Management of bone metastases in refractory prostate cancer--role of denosumab. Clin Interv Aging. 2012; 7:363-72. PMC: 3459574. DOI: 10.2147/CIA.S27930. View

13.

Favia G, Pilolli G, Maiorano E . Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009; 45(3):406-13. DOI: 10.1016/j.bone.2009.05.008. View

14.

Ferretti G, Fabi A, Carlini P, Papaldo P, Fei P, Di Cosimo S . Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005; 69(1):35-43. DOI: 10.1159/000087286. View

15.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

16.

Hoefert S, Eufinger H . Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2010; 69(2):362-80. DOI: 10.1016/j.joms.2010.06.200. View

17.

Petcu E, Ivanovski S, Wright R, Slevin M, Miroiu R, Brinzaniuc K . Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?. Diagn Pathol. 2012; 7:78. PMC: 3479027. DOI: 10.1186/1746-1596-7-78. View

18.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View

19.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

20.

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R . Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-9. DOI: 10.1200/JCO.2010.29.7101. View